Uterine artery embolization for symptomatic uterine fibroids

Janesh K Gupta; Anju Sinha; M A Lumsden; Martha Hickey

doi:10.1002/14651858.CD005073.pub4

Cochrane Database of Systematic Reviews

Embolización de la arteria uterina para los fibromas uterinos sintomáticos

Información

DOI:

https://doi.org/10.1002/14651858.CD005073.pub4 Copiar DOI

Base de datos:

Cochrane Database of Systematic Reviews

Versión publicada:

26 diciembre 2014see what's new

Tipo:

Intervention

Etapa:

Review

Grupo Editorial Cochrane:

Grupo Cochrane de Ginecología y fertilidad

Copyright:

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

Janesh K Gupta

Correspondencia a: Academic Department of Obstetrics and Gynaecology, University of Birmingham, Birmingham, UK

[email protected]
Anju Sinha

Obstetrics & Gynaecology, University Hospital of Wales, Cardiff, UK
M A Lumsden

Developmental Medicine, Reproductive & Maternal Medicine, University of Glasgow, Glasgow, UK
Martha Hickey

The University of Melbourne, The Royal Women's Hospital, Melbourne, Australia

Contributions of authors

JKG was the principal author with AS in all versions of the review. MAL and MH provided feedback and checks of the drafts.

Sources of support

Internal sources

Cochrane Menstrual Disorders and Subfertility Review Group in Auckland, New Zealand.

Search Strategy

External sources

No sources of support supplied

Declarations of interest

Mary Ann Lumsden took part in the REST clinical trial.

Acknowledgements

We would like to thank the Cochrane Menstrual Disorders and Subfertility Review Group in Auckland.

We would also like to thank the corresponding authors Ms Isabel Pinto and Ms Lilian Murray who took time to respond to our request for further information.

Version history

Published

Title

Stage

Authors

Version

2014 Dec 26

Uterine artery embolization for symptomatic uterine fibroids

Review

Janesh K Gupta, Anju Sinha, M A Lumsden, Martha Hickey

https://doi.org/10.1002/14651858.CD005073.pub4

2012 May 16

Uterine artery embolization for symptomatic uterine fibroids

Review

Janesh K Gupta, Anju Sinha, M.A Lumsden, Martha Hickey

https://doi.org/10.1002/14651858.CD005073.pub3

2006 Jan 25

Uterine artery embolization for symptomatic uterine fibroids

Review

Janesh K Gupta, Anju Sinha, Mary Ann Lumsden, Martha Hickey

https://doi.org/10.1002/14651858.CD005073.pub2

2005 Jan 24

Uterine artery embolisation for symptomatic uterine fibroids

Protocol

Janesh K Gupta, Martha Hickey, Mary Ann Lumsden, Michael Broder, Letsebe Darius R Tsatsi

https://doi.org/10.1002/14651858.CD005073

Differences between protocol and review

Assessment of patient satisfaction at up to 24 months and at 5 years, and health‐related quality of life were added as outcomes.

At the 2014 update we decided to limit the possible interventions included in this review, to avoid potential overlap with reviews covering new medical interventions for uterine fibroids. Medical interventions including gonadotrophin‐releasing hormone analogues are now excluded.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Female; Humans;

Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 3

Forest plot of comparison: 1 UAE versus surgery, outcome: 1.1 Satisfaction with treatment up to 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 4

Forest plot of comparison: 1 UAE versus surgery, outcome: 1.2 Satisfaction with treatment at 5 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 5

Forest plot of comparison: 1 UAE versus surgery, outcome: 1.3 Live birth.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 6

Forest plot of comparison: 1 UAE versus surgery, outcome: 1.10 Further interventions within 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 UAE versus surgery, Outcome 1 Satisfaction with treatment up to 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 UAE versus surgery, Outcome 2 Satisfaction with treatment at 5 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 UAE versus surgery, Outcome 3 Live birth.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 UAE versus surgery, Outcome 4 Adverse events: intraprocedural complications.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 UAE versus surgery, Outcome 5 Adverse events: Need for blood transfusion.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 UAE versus surgery, Outcome 6 Adverse events: minor postprocedural complications.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 UAE versus surgery, Outcome 7 Adverse events: major postprocedural complications within one year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 UAE versus surgery, Outcome 8 Adverse events: later minor postprocedural complications.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 UAE versus surgery, Outcome 9 Adverse events: major postprocedural complications.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 UAE versus surgery, Outcome 10 Further interventions within 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.11

Comparison 1 UAE versus surgery, Outcome 11 Further interventions within 5 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.12

Comparison 1 UAE versus surgery, Outcome 12 Unscheduled readmission rate within 4‐6 weeks.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.13

Comparison 1 UAE versus surgery, Outcome 13 Cost: duration of procedure (minutes).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.14

Comparison 1 UAE versus surgery, Outcome 14 Cost: length of hospital stay (days).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.15

Comparison 1 UAE versus surgery, Outcome 15 Cost: resumption of normal activities (days).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.16

Comparison 1 UAE versus surgery, Outcome 16 FSH levels >40 IU/L (within 2 years).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.17

Comparison 1 UAE versus surgery, Outcome 17 FSH levels >10 IU/L (within 6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.18

Comparison 1 UAE versus surgery, Outcome 18 Fibroid recurrence within 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.19

Comparison 1 UAE versus surgery, Outcome 19 Pregnancy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.20

Comparison 1 UAE versus surgery, Outcome 20 UAE versus myomectomy: Health related quality of life at one year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.21

Comparison 1 UAE versus surgery, Outcome 21 UAE versus hysterectomy or myomectomy: SF‐36 within 1 year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Summary of findings for the main comparison. Uterine artery embolization (UAE) compared to surgery for symptomatic uterine fibroids

UAE compared to surgery for symptomatic uterine fibroids
Population: women with symptomatic uterine fibroids Intervention: UAE Comparison: surgery
Outcomes	*Illustrative comparative risks (95% CI)**		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Surgery	UAE
Satisfaction with treatment up to 24 months	861 per 1000	853 per 1000 (785 to 901)	OR 0.94 (0.59 to 1.48)	640 (6 RCTs)	⊕⊕⊕⊝ MODERATE ^1,2
Satisfaction with treatment at 5 years	876 per 1000	864 per 1000 (761 to 927)	OR 0.90 (0.45 to 1.80)	295 (2 RCTs)	⊕⊕⊕⊝ MODERATE ¹
Live birth ‐ UAE versus myomectomy	475 per 1000	190 per 1000 (67 to 432)	OR 0.26 (0.08 to 0.84)	66 (1 RCT)	⊕⊝⊝⊝ VERY LOW ^3,4
Adverse events: intra‐procedural complications	63 per 1000	57 per 1000 (27 to 117)	OR 0.91 (0.42 to 1.97)	452 (4 RCTs)	⊕⊕⊝⊝ LOW^5,6,7
Adverse events: minor post‐procedural complications within one year	230 per 1000	373 per 1000 (296 to 456)	OR 1.99 (1.41 to 2.81)	735 (6 RCTs)	⊕⊕⊕⊝ MODERATE ^1,2
Adverse events: major post‐procedural complications within one year	69 per 1000	46 per 1000 (24 to 85)	OR 0.65 (0.33 to 1.26)	611 (5 RCTs)	⊕⊕⊕⊝ MODERATE ^1,5,7
Further interventions within 2 years	71 per 1000	222 per 1000 (149 to 317)	OR 3.72 (2.28 to 6.04)	732 (6 RCTs)	⊕⊕⊕⊝ MODERATE ^1,2,8
The basis for the assumed risk* is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
¹Studies unblinded ²Two studies did not fully explain randomisation and allocation concealment, but quality not downgraded for this as their omission from analysis did not substantially change the findings ³ Wide confidence intervals compatible with substantial harm from UAE or with no effect ⁴Includes only those trial participants who wished to conceive (66/121) ⁵One study did not fully explain methods of randomisation and allocation concealment, but omission of this study did not substantially affect the findings ⁶Low event rate ⁷Wide confidence intervals compatible with substantial harm or benefit from either intervention, or with no effect ⁸Some statistical heterogeneity (I² = 45%); quality not downgraded for this as direction of effect is consistent

Summary of findings for the main comparison. Uterine artery embolization (UAE) compared to surgery for symptomatic uterine fibroids

Ir a la tabla de la revisión

Comparison 1. UAE versus surgery

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Satisfaction with treatment up to 24 months Show forest plot	6	640	Odds Ratio (M‐H, Fixed, 95% CI)	0.94 [0.59, 1.48]

1.1 UAE versus hysterectomy	3	266	Odds Ratio (M‐H, Fixed, 95% CI)	0.63 [0.30, 1.32]
1.2 UAE versus hysterectomy or myomectomy	2	264	Odds Ratio (M‐H, Fixed, 95% CI)	1.29 [0.64, 2.58]
1.3 UAE versus myomectomy	1	110	Odds Ratio (M‐H, Fixed, 95% CI)	1.05 [0.33, 3.36]
2 Satisfaction with treatment at 5 years Show forest plot	2	295	Odds Ratio (M‐H, Fixed, 95% CI)	0.90 [0.45, 1.80]

2.1 UAE versus hysterectomy	1	156	Odds Ratio (M‐H, Fixed, 95% CI)	0.71 [0.29, 1.78]
2.2 UAE versus hysterectomy or myomectomy	1	139	Odds Ratio (M‐H, Fixed, 95% CI)	1.25 [0.42, 3.67]
3 Live birth Show forest plot	1		Odds Ratio (M‐H, Fixed, 95% CI)	Subtotals only

3.1 UAE versus myomectomy	1	66	Odds Ratio (M‐H, Fixed, 95% CI)	0.26 [0.08, 0.84]
4 Adverse events: intraprocedural complications Show forest plot	4	452	Odds Ratio (M‐H, Fixed, 95% CI)	0.91 [0.42, 1.97]

4.1 UAE versus hysterectomy	2	209	Odds Ratio (M‐H, Fixed, 95% CI)	1.23 [0.44, 3.44]
4.2 UAE versus myomectomy	2	243	Odds Ratio (M‐H, Fixed, 95% CI)	0.61 [0.18, 2.03]
5 Adverse events: Need for blood transfusion Show forest plot	2	277	Odds Ratio (M‐H, Fixed, 95% CI)	0.07 [0.01, 0.52]

5.1 UAE versus hysterectomy	1	156	Odds Ratio (M‐H, Fixed, 95% CI)	0.04 [0.00, 0.67]
5.2 UAE versus myomectomy	1	121	Odds Ratio (M‐H, Fixed, 95% CI)	0.21 [0.01, 4.47]
6 Adverse events: minor postprocedural complications Show forest plot	6	735	Odds Ratio (M‐H, Fixed, 95% CI)	1.99 [1.41, 2.81]

6.1 UAE versus hysterectomy	2	211	Odds Ratio (M‐H, Fixed, 95% CI)	2.12 [1.13, 3.96]
6.2 UAE versus hysterectomy or myomectomy	2	281	Odds Ratio (M‐H, Fixed, 95% CI)	2.51 [1.49, 4.23]
6.3 UAE versus myomectomy	2	243	Odds Ratio (M‐H, Fixed, 95% CI)	1.23 [0.62, 2.44]
7 Adverse events: major postprocedural complications within one year Show forest plot	5	611	Odds Ratio (M‐H, Fixed, 95% CI)	0.65 [0.33, 1.26]

7.1 UAE versus hysterectomy	2	211	Odds Ratio (M‐H, Fixed, 95% CI)	1.00 [0.22, 4.58]
7.2 UAE versus hysterectomy or myomectomy	1	157	Odds Ratio (M‐H, Fixed, 95% CI)	0.73 [0.30, 1.74]
7.3 UAE versus myomectomy	2	243	Odds Ratio (M‐H, Fixed, 95% CI)	0.29 [0.06, 1.50]
8 Adverse events: later minor postprocedural complications Show forest plot	3		Odds Ratio (M‐H, Fixed, 95% CI)	Subtotals only

8.1 UAE versus hysterectomy or myomectomy (to 5 years)	2	268	Odds Ratio (M‐H, Fixed, 95% CI)	2.93 [1.73, 4.93]
8.2 UAE versus myomectomy (1 month‐2 years)	1	120	Odds Ratio (M‐H, Fixed, 95% CI)	1.82 [0.56, 5.94]
9 Adverse events: major postprocedural complications Show forest plot	3	388	Odds Ratio (M‐H, Fixed, 95% CI)	0.56 [0.27, 1.18]

9.1 UAE versus hysterectomy or myomectomy (to 5 years)	2	268	Odds Ratio (M‐H, Fixed, 95% CI)	0.56 [0.27, 1.18]
9.2 UAE versus myomectomy (1 month‐2 years)	1	120	Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Further interventions within 2 years Show forest plot	6	732	Odds Ratio (M‐H, Fixed, 95% CI)	3.72 [2.28, 6.04]

10.1 UAE versus hysterectomy	2	209	Odds Ratio (M‐H, Fixed, 95% CI)	2.99 [1.31, 6.80]
10.2 UAE versus hysterectomy or myomectomy	2	281	Odds Ratio (M‐H, Fixed, 95% CI)	2.83 [1.29, 6.24]
10.3 UAE versus myomectomy	2	242	Odds Ratio (M‐H, Fixed, 95% CI)	6.89 [2.60, 18.27]
11 Further interventions within 5 years Show forest plot	2	289	Odds Ratio (M‐H, Fixed, 95% CI)	5.79 [2.65, 12.65]

11.1 UAE versus hysterectomy	1	145	Odds Ratio (M‐H, Fixed, 95% CI)	3.43 [1.41, 8.30]
11.2 UAE versus hysterectomy or myomectomy	1	144	Odds Ratio (M‐H, Fixed, 95% CI)	20.34 [2.68, 154.59]
12 Unscheduled readmission rate within 4‐6 weeks Show forest plot	2	278	Risk Difference (M‐H, Fixed, 95% CI)	0.14 [0.05, 0.22]

12.1 UAE versus hysterectomy	1	157	Risk Difference (M‐H, Fixed, 95% CI)	0.23 [0.09, 0.38]
12.2 UAE versus myomectomy	1	121	Risk Difference (M‐H, Fixed, 95% CI)	0.02 [‐0.04, 0.07]
13 Cost: duration of procedure (minutes) Show forest plot	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

13.1 UAE versus hysterectomy	1	156	Mean Difference (IV, Fixed, 95% CI)	‐16.40 [‐26.04, ‐6.76]
13.2 UAE versus myomectomy	1	121	Mean Difference (IV, Fixed, 95% CI)	‐49.7 [‐58.76, ‐40.64]
14 Cost: length of hospital stay (days) Show forest plot	7		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

14.1 UAE versus hysterectomy	3		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
14.2 UAE versus hysterectomy or myomectomy	2		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
14.3 UAE versus myomectomy	2		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
15 Cost: resumption of normal activities (days) Show forest plot	5		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

15.1 UAE versus hysterectomy	2	188	Mean Difference (IV, Fixed, 95% CI)	‐22.85 [‐27.30, ‐18.40]
15.2 UAE versus hysterectomy or myomectomy	2	220	Mean Difference (IV, Fixed, 95% CI)	‐13.68 [‐16.05, ‐11.30]
15.3 UAE versus myomectomy	1	121	Mean Difference (IV, Fixed, 95% CI)	‐10.20 [‐13.60, ‐6.80]
16 FSH levels >40 IU/L (within 2 years) Show forest plot	2	297	Odds Ratio (M‐H, Fixed, 95% CI)	1.01 [0.53, 1.94]

16.1 UAE versus hysterectomy	1	153	Odds Ratio (M‐H, Fixed, 95% CI)	0.70 [0.32, 1.54]
16.2 UAE versus hysterectomy or myomectomy	1	144	Odds Ratio (M‐H, Fixed, 95% CI)	2.35 [0.64, 8.68]
17 FSH levels >10 IU/L (within 6 months) Show forest plot	1	120	Odds Ratio (M‐H, Fixed, 95% CI)	4.8 [0.97, 23.64]

17.1 UAE versus myomectomy	1	120	Odds Ratio (M‐H, Fixed, 95% CI)	4.8 [0.97, 23.64]
18 Fibroid recurrence within 2 years Show forest plot	1	120	Odds Ratio (M‐H, Fixed, 95% CI)	1.32 [0.38, 4.57]

18.1 UAE versus myomectomy	1	120	Odds Ratio (M‐H, Fixed, 95% CI)	1.32 [0.38, 4.57]
19 Pregnancy Show forest plot	1	66	Odds Ratio (M‐H, Fixed, 95% CI)	0.29 [0.10, 0.85]

19.1 UAE versus myomectomy	1	66	Odds Ratio (M‐H, Fixed, 95% CI)	0.29 [0.10, 0.85]
20 UAE versus myomectomy: Health related quality of life at one year Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

20.1 USF‐QOL end scores	1	122	Mean Difference (IV, Fixed, 95% CI)	‐13.40 [‐21.41, ‐5.39]
20.2 USF‐QOL change scores	1	122	Mean Difference (IV, Fixed, 95% CI)	‐7.60 [‐17.55, 2.35]
21 UAE versus hysterectomy or myomectomy: SF‐36 within 1 year Show forest plot	2	1405	Mean Difference (IV, Fixed, 95% CI)	9.14 [8.04, 10.23]

21.1 Physical function	2	281	Mean Difference (IV, Fixed, 95% CI)	7.77 [5.83, 9.70]
21.2 Social function	2	281	Mean Difference (IV, Fixed, 95% CI)	6.14 [2.71, 9.58]
21.3 Mental Health	2	281	Mean Difference (IV, Fixed, 95% CI)	12.00 [9.50, 14.50]
21.4 Emotional role	2	281	Mean Difference (IV, Fixed, 95% CI)	10.28 [7.96, 12.60]
21.5 Vitality	2	281	Mean Difference (IV, Fixed, 95% CI)	8.75 [6.09, 11.41]

Comparison 1. UAE versus surgery

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet

Scolaris Content Display Scolaris Content Display

Embolización de la arteria uterina para los fibromas uterinos sintomáticos

Información